IP Library Granted Patent US 7,754,941
Granted Patent B2
US 7,754,941 · App. 11/729,242 · Granted Jul 13, 2010

Animal models for demyelination disorders

Assignee: University of Chicago
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,941
App. No.
11/729,242
Granted
Jul 13, 2010
Kind
B2
Abstract

This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.

Claims (11)

1. A method of testing for a small organic compound that modulates neuronal demyelination in the nervous system, comprising:

(a) administering said small organic compound to a transgenic mouse animal, whose genome comprises:

(i) a stably integrated transgenic nucleotide sequence encoding interferon-gamma (IFN-γ) operably linked to an inducible promoter; and

(ii) a heterozygous knock-out of the endogenous pancreatic endoplasmic reticulum (ER) kinase gene (PERK), wherein upon expression of said IFN-γ said transgenic mouse exhibits a greater degree of demyelination relative to a transgenic animal-mouse having a stably integrated transgenic nucleotide sequence encoding IFN-γ as in (i), but lacking said heterozygous knock-out of the PERK gene;

(b) determining whether said small organic compound effectively modulates neuronal demyelination in the nervous system.

2. The method of claim 1 , wherein said determining in step (b) is by characterizing a loss of oligodendrocytes or Schwann cells in said nervous system.

3. The method of claim 1 , wherein said determining in step (b) characterizing is by a decrease in myelinated axons in said nervous system.

4. The method of claim 1 , wherein said determining in step (b) is by characterizing a reduction in the level of an oligodendrocyte marker or a Schwann cell marker.

5. The method of claim 4 , wherein said oligodendrocyte marker is proteolipid protein (PLP).

6. The method of claim 1 , wherein said determining in step (b) involves an immunoassay.

7. The method of claim 1 , wherein said determining in step (b) involves a hybridization assay.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 27, 2012
From: UNIVERSITY OF CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028852/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2007
From: POPKO, BRIAN; LIN, WENSHENG
To: UNIVERISTY OF CHICAGO
Reel/Frame 019547/0998 →
Continuity (4)
Provisional Application 6079200700 · Apr 14, 2006
Provisional Application 6074482600 · Apr 13, 2006
Provisional Application 6069069100 · Jun 14, 2005
Related Publication 20080096202A1 · Apr 24, 2008